<div id="readability-page-1"><p>Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) is projected to release its  Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Karyopharm Therapeutics to post earnings of ($2.26) per share and revenue of $33.16 million for the quarter. Parties can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:00 AM ET.</p><h2>Karyopharm Therapeutics Trading Up 2.8%</h2><p>Shares of NASDAQ KPTI traded up $0.17 during midday trading on Friday, reaching $6.26. The company had a trading volume of 520,560 shares, compared to its average volume of 406,867. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $10.38. The business's 50-day simple moving average is $6.79 and its 200 day simple moving average is $6.12. The stock has a market cap of $114.62 million, a P/E ratio of -0.43 and a beta of 0.21. </p><h2>Analyst Ratings Changes</h2><p>Several analysts have weighed in on KPTI shares. Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics in a research note on Thursday. They set an &#34;overweight&#34; rating on the stock. Wall Street Zen raised shares of Karyopharm Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th. Royal Bank Of Canada cut their price target on Karyopharm Therapeutics from $30.00 to $19.00 and set an &#34;outperform&#34; rating on the stock in a research report on Tuesday, November 4th. HC Wainwright raised Karyopharm Therapeutics from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $15.00 price objective for the company in a report on Monday, October 13th. Finally, The Goldman Sachs Group  set a $12.00 target price on Karyopharm Therapeutics in a report on Wednesday, December 17th. Six equities research analysts have rated the stock with a Buy rating and one  has assigned  a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $14.83.</p><p><b>Check Out Our Latest Analysis on Karyopharm Therapeutics</b></p><h2>Institutional Trading of Karyopharm Therapeutics</h2><p>Several institutional investors have recently bought and sold shares of the business. Baird Financial Group Inc. acquired a new position in shares of  Karyopharm Therapeutics during the 2nd quarter worth approximately $45,000.  XTX Topco Ltd purchased a new stake in  Karyopharm Therapeutics in the 2nd quarter worth $56,000.  Bridgeway Capital Management LLC purchased a new stake in  Karyopharm Therapeutics in the 2nd quarter worth $163,000.  ADAR1 Capital Management LLC acquired a new position in  Karyopharm Therapeutics during the third quarter worth $164,000.  Finally, Bank of America Corp DE lifted its holdings in  Karyopharm Therapeutics by 26.8% during the second quarter. Bank of America Corp DE now owns 168,534 shares of the company's stock valued at $726,000 after purchasing an additional 35,626 shares in the last quarter. 66.44% of the stock is owned by institutional investors and hedge funds. </p><h2>About Karyopharm Therapeutics</h2> (Get Free Report)<p>Karyopharm Therapeutics <span>NASDAQ: KPTI<span></span></span> is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company's lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm's pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.  </p><p>Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Karyopharm Therapeutics</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The day the gold market broke</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Your Bank Account Is No Longer Safe</li><li>He just nailed another gold prediction …</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1BUSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1BUSQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Karyopharm Therapeutics Right Now?</h2><p>Before you consider Karyopharm Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Karyopharm Therapeutics wasn't on the list.</p><p>While Karyopharm Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KPTI

<p>Karyopharm Therapeutics (NASDAQ: KPTI) is set to announce its Q4 2025 earnings on February 12, 2026, with expectations of a loss of $2.26 per share and revenue of $33.16 million. The stock recently traded up 2.8% to $6.26, with a market cap of $114.62 million. Analysts have mixed ratings, with Cantor Fitzgerald initiating coverage with an "overweight" rating, while Royal Bank of Canada lowered its price target. Institutional investors hold 66.44% of the stock, and Karyopharm focuses on developing drugs targeting the nuclear export protein XPO1.</p>

Karyopharm Therapeutics (KPTI) Expected to Announce Earnings on Thursday